Oberland Capital
Venture debtNew York · Growth–Late Stage · 20 people tracked
Also known as OBERLAND CAPITAL MANAGEMENT LLC
Find your way into Oberland Capital
12,071 people in our graph share verified history with the Oberland Capital team — schools, employers, funds. One of them is your warm intro.
.jpeg)
Investment thesis
Oberland Capital focuses on funding innovation across the global healthcare industry through flexible, customized investment structures. Its financing solutions include the monetization of royalty streams, acquisition of future product revenues, creation of project-based financing structures, and investments in traditional debt and equity. The firm aims to accelerate the development and commercialization of promising healthcare products to create value for partners and transform patient care.
Source: firm website, verified Sep 1, 2026.
Team · 20 people
from the firm's website
What they invest in
from 18 of 19 portfolio companiesBiotech ×17Medical Devices ×13Healthtech ×12Deep Tech ×5Digital Health ×4Advanced Manufacturing ×1
HQs:United States×15Switzerland×1United Kingdom×1
Investments · 19 tracked
founders shown can be your intro pathAgenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.
BiotechHealthtechLexington, US
Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)Steven O'Day(Chief Medical Officer)in
Co-investorsAdvent Life SciencesGrazia Equity GmbHHEALTHCARE ROYALTY PARTNERSCommodore CapitalInvusLigand Pharmaceuticals+1 more
BillionToOne is a precision diagnostics company that uses molecular counting technology to develop non-invasive prenatal screening and liquid biopsy tests for early disease detection.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Oguzhan Atay, PhD(Co-Founder, CEO, and Board Chair)David Tsao, PhD(Co-Founder, CTO, and Board Member)Oguzhan Atay(Founder)inDavid Tsao(Founder/CTO)inSukrit Silas(Cofounder)in
Co-investors500 Emerging Europe500 GlobalAsymmetry VenturesCivilization Ventures Management, Llce2vcFifty Years+15 more
Biohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy.
BiotechHealthtechMedical DevicesConnecticut, US
Vlad Coric, M.D.(Chairman & Chief Executive Officer)in
Co-investorsRA CapitalSixth Street
ClearPoint Neuro develops neurosurgical guidance systems and platforms that enable precise navigation to the brain and spine for device, cell, and gene therapy procedures.
BiotechDeep TechDigital HealthHealthtechMedical DevicesSolana Beach, US
Humacyte is a regenerative medicine company that develops a bioengineered, human-derived Acellular Tissue Engineered Vessel (ATEV) along with a scalable cell sourcing and manufacturing platform.
BiotechHealthtechMedical DevicesMorrisville, US
Laura E. Niklason(Director)inLaura Niklason, MD, PhD(Founder)inTed Lithgow(Executive Officer)inPaul Boyer(Executive Officer)inCarrie S. Cox(Executive Officer, Director)
BoardRobert Anderson(Director)
Co-investorsFirst In VenturesFresenius Medical Care Ventures
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases (IRDs) and other retinal and refractive disorders.
BiotechDeep TechDigital HealthHealthtechMedical DevicesRaleigh, US
George Magrath(Chief Executive Officer)inBen Yerxa(President)inRobert Gagnon(Chief Financial Officer)Joe Schachle(Chief Operating Officer)inAsh Jayagopal(Chief Scientific and Development Officer)inSally Tucker(Chief Medical Officer)in
Co-investorsMichigan Capital Network
BiotechFarmington Hills, US
Dr. Jean Bennett(Director)Dr. Benjamin Yerxa(Director, Executive Officer)Bernhard Hoffmann(Executive Officer)Nirav Jhaveri(Executive Officer)inAsh Jayagopal(Executive Officer)inAmy Rabourn(Executive Officer)in
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.
BiotechMedical DevicesNeedham, US
Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)inCATHY CAREW(Executive Officer)inJONATHAN PACHTER(Executive Officer)inROB GAGNON(Executive Officer)in
Co-investorsBessemer Venture PartnersCardinal PartnersForesite CapitalLightstone VenturesLongwood FundOrbiMed
Meira GTx develops genetic medicine treatments for patients with devastating diseases, leveraging expertise in drug development and manufacturing.
BiotechDeep TechHealthtechMedical Devices
Co-investorsAlbionVCUCL Technology Fund
BiotechMiramar, US
Hing C Wong(Executive Officer, Director)Peter Rhode(Executive Officer)
BoardAdam Waldman(Director)Fred Middleton(Director)C. Boyder Gray(Director)
Co-investorsSanderling Ventures
Axogen develops surgical technologies and solutions for peripheral nerve repair procedures across various anatomical locations.
HealthtechMedical Devices
Michael Dale(President, Chief Executive Officer and Board Director)in
BoardPaul G. Thomas(Chairman of the Board)Amy Wendell(Director)William Burke(Director)John H. Johnson(Director)Alan M. Levine(Director)
Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.
BiotechHealthtech
Co-investorsAdvent Life SciencesEcoR1 CapitalForesite CapitalMedicxiScion Life SciencesVida Ventures+1 more
BiotechAnn Arbor, US
Antonio M. Gotto, Jr.(Director)Tim M. Mayleben(Executive Officer, Director)Gilbert S. Omenn(Director)Daniel Janney(Director)Dov A. Goldstein(Director)Roger S. Newton(Director)
Co-investorsAisling CapitalAlta PartnersArboretum VenturesARCHIMED JapanAsset Management CompanyCanaan Partners+2 more
Invitae provides genetic testing services to patients and clinicians across the United States, offering broad test offerings and genetic counseling to inform health decisions at every stage of life.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Sean George(Executive Officer, Director)inRandal Scott(Executive Officer, Director)Shelly Guyer(Executive Officer)inLee Bendekgey(Executive Officer)inGeoffrey Crouse(Director)
BoardEric Aguiar(Director)in
Co-investorsCivilization Ventures Management, LlcDecheng CapitalFifty YearsManta Ray VenturesPrefix CapitalTech Wildcatters+1 more
Acquired by Shire in 2014 (now part of Takeda).
BiotechMedical Devices
Co-investorsFrazier Life SciencesLongitude CapitalRiverVest Venture Partners
NorthStar Medical Technologies develops and commercializes innovative nuclear medicine products and technologies for the pharmaceutical and life sciences industries.
BiotechDeep TechMedical DevicesBeloit, US
Oxford Biomedica is a biopharmaceutical contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, lentiviral vector technologies, and bioprocessing solutions.
Advanced ManufacturingBiotechDeep TechHealthtechMedical DevicesOxford, GB
Dr. Frank Mathias(Chief Executive Officer)inDr. Lucinda Crabtree(Chief Financial Officer)
BoardDr. Roch Doliveux(Non-Executive Chair)
Co-investorsNovo Holdings
Co-investorsAvoro Capital AdvisorsKurma PartnersSunstone Capital
Exits · 9
IPOs and acquisitions across the tracked portfolioAgenusNASDAQ: AGENBillionToOneNASDAQ: BLLNBiohavenNYSE: BHVNClearpointneuroNASDAQ: CLPTHumacyteNASDAQ: HUMAOpus GeneticsNASDAQ: IRDOpus GeneticsNASDAQ: IRDVerastemNASDAQ: VSTMLumena Pharmaceuticalsacq. by Shire
Portfolio news
latest coverage across their companiesOpus Genetics · investing.com · Aug 19, 2026
Agenus · simplywall.st · Aug 15, 2026
Humacyte · stocktitan.net · Aug 12, 2026
Opus Genetics · stocktitan.net · Aug 6, 2026
BillionToOne · investing.com · Jul 13, 2026
Verastem · insidermonkey.com · Jul 3, 2026
Centessa Pharmaceuticals · streetinsider.com · Jun 24, 2026
Fund performance · per public LP disclosures · 3
as of Dec 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Oberland Capital Healthcare III LPLPs: Texas Municipal Retirement System | — | — | 2.9% | 1.11x | 0.19x |
| Oberland Capital Healthcare Solutions Co-Invest LPLPs: Texas Municipal Retirement System | — | — | 23.5% | 1.35x | 0.56x |
| Oberland Capital Healthcare Solutions LPLPs: Texas Municipal Retirement System | — | — | 10.6% | 1.22x | 0.58x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has Oberland Capital made?
- Oberland Capital has 18 tracked investments, 2 of which have exited via acquisition or IPO.
- What stage does Oberland Capital invest at?
- Oberland Capital invests at the Growth, Late Stage stages.
- What is Oberland Capital's typical check size?
- Oberland Capital typically writes checks of $50M – $300M.
- What sectors does Oberland Capital focus on?
- Oberland Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Oberland Capital located?
- Oberland Capital is headquartered in New York, US.
- Who does Oberland Capital co-invest with?
- Oberland Capital most often shares deals with Advent Life Sciences, Civilization Ventures Management, Llc, Fifty Years, among 58 tracked co-investors.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.
Vensana Capital is a venture capital and growth equity investment firm focused on partnering with entrepreneurs building breakthrough medical technology innovations to transform healthcare.
Visionary Ventures is a venture capital fund investing from Series A through commercialization, leveraging partnerships with Key Opinion Leaders, industry experts, and strategic acquirers to source and vet deals.